The European Commission authorized a new preventive treatment for HIV in the European Union, according to a statement of the “Glyad” medicines that it makes.
This medicine, which was called in Europe, does not require YEYTUO (in the United States “Yeztugo” only two annual injections, while the majority of its competing products are eating a tablet daily.
This simplified method of giving the drug be hoped to improve the prevention of the risk groups, especially in developing countries.
The Pharmaceutical Committee for the European Agency for Humanities issued a positive opinion in July regarding the latter of “Yito”.
A specialist in infectious diseases at the Laripusiere and San Lewis Hospital in Paris, Professor Jean -Michel Molina, noted that “about 25,000 new HIV infections are recorded annually in European Union countries and the European Economic Zone.”
He believed that this number clearly shows that “the current prevention methods are not useful with all those who need them, especially the risk groups.”
Last June, the United States was released.
The two clinical experiments conducted by the company for preventive treatment showed a decrease in the risk of HIV transmission by more than 99.9% in adults and adolescents.
Although they saw that this drug provides an unprecedented effectiveness, and they expected to make a qualitative shift in AIDS control, raising its high price and thus the difficulty of obtaining it other concerns.
“Glyad” told AFP in June that the cost of “Yazogo” in the United States will exceed 28 thousand dollars annually per patient.
After appeals from experts and patients for patients for the most famous, Glyad reached the 2024 agreement with manufacturers to produce and selling low -cost -cost -cost -cost drugs in more than a hundred developing countries, and providing many additional doses.
The World Fund, a partnership between the public and private sectors, announced in July that it had signed a contract with “Glyad” to provide preventive treatment for low and medium -income countries.